中国医学科学院基础医学研究所流行病学与统计学系研究员，博士生导师，中国医学科学院基础医学研究所流行病与卫生统计学系课题组长（PI)。先后获得白求恩医科大学营养与食品卫生专业学士学位、中国协和医科大学社会医学与卫生事业管理硕士学位和流行病学与卫生统计学博士学位。2007-2009年赴Johns Hopkins大学公共卫生学院遗传流行病学系做博士后。目前担任中华医学会临床流行病学分会委员，中华医学会结核病学分会临床流行病学专委会副主任委员，中国中药协会真实世界研究专业委员会委员，国家药监局海南真实世界研究国家重点实验室特聘专家，妇幼健康研究会生育调控学会专业委员会常务委员，中国研究型医院学会罕见病分会理事，北京医学会临床流行病学分会常委、中华医学会肝病学会、消化病学会等多个专业学会的方法学组成员等。

光明磊落，永怀对科学的热情，从不放弃是我们对你的期待；相互扶持、彼此衬托是我们对你的承诺；东单三条，我们在这里等着你。

近五年课题或子课题负责人承担项目：

瘦型非酒精性脂肪性肝病的亚型分类、健康效应及代谢物遗传网络研究（国家自然科学基金）

社区人群为基础的代谢相关脂肪性肝病风险预测模型体系研究（首都卫生发展科研专项）

中国医学科学院全生命周起队列研究与信息化建设（中国医学科学院医学与健康科技创新工程协同创新项目）

北京市乙肝抗病毒治疗药物的可及性、可支付能力研究及卫生经济学评价（科技部传染病重大专项）

北京市丙型病毒性肝炎“发现-转诊-治疗”一体化综合管理模式研究（首都卫生发展科研专项）

替诺福韦酯治疗慢性乙型肝炎的疗效及安全性评价（吴阶平医学基金会）

基于队列的环境因素和消化道微生态变化对我国消化系统相关疾病健康效应研究（中国医学科学院医学与健康科技创新工程协同创新项目）

Baseline survey on household catastrophic cost due to TB in China (supported by WHO)

全国消化系统疾病流行病学调查“（卫生公益行业基金）

过去10年中，作为课题负责人或子课题负责人承担了国家自然科学基金、科技部传染病重大专项、卫生部行业基金、世界卫生组织等多项课题；同时还先后承担了卫生部临床重点学科、行业基金、北京市科委等一些重大临床课题的流行病学研究设计及统计分析工作。

在SCI收录的杂志中发表论文100余篇,其中第一作者（含共同）或通讯作者（含共同）以第一作者（或并列作者）、通讯作者（或并列通讯）在Nature genetics, Clinical Gastroenterology and Hepatology,Hepatobiliary Surg Nutrition, Metabolism Clinical Experimental, LiverInternational, Hepatology international, Molecular Carcinogenesis等杂志发表文章50余篇，包括ESI高引用论文2篇。先后获先后获中国协和医科大学中国医学科学院优秀博士论文奖，中华医学科技进步奖二等奖，教育部高等学校科学研究成果奖二等奖，北京市优秀人才资助各一项。

2020年及以后发表文章情况(通讯作者或共同通讯作者，按照文章发表时间顺序从后到前）：

1.      CaoXF, Guo TL, Xin HN, Du J, Yang CL, Feng BX, He YJ, Shen LY, Di YZ, Li ZH, ChenYX, Liang JG, Jin Q, Wang L*, Gao L*. Cost-effetiveness of latent tuberculosisinfection testing and treatment with 6-week regimen among key population inrural communities in China: a decision analysis study. Euro J Clin Microbiol.2024, doi: 10.1007/s10096-024-04777-z

2.     Wu LP, Lan YQ, Yu Z, Wang YH, Liao W,Zhang GQ, Wang L. Blood manganeseand non-alcoholic fatty liver disease in a high manganeseexposure area in China. J Health Population Nutr. 2023, 32:118

3.     Zhang D, Wu SL, Lan YQ, Chen SH, Wang YH,Sun YY, Lu Y, Liao W, Wang L. Essential metal mixturesexposure and NAFLD: A cohort-based case-control study in northern Chinese maleadults. Chemosphere 2023, 139598

4.      YuanXJ, Wang XM, Wu SL, Chen SH, Wang YH, Wang JR, Lu Y, Sun YY, Fu QJ, Wang L. AssociationsBetween Metabolic Dysfunction-Associated Fatty Liver Disease and ExtrahepaticCancers: A Cohort in China. Hepatobiliary Surg Nutrition, 2023,12(5): 671-681. doi:10.21037/hbsn-21-546

5.     Yang CL, Wu SL, Lan YQ, Chen SH, Zhang D,Wang YH, Sun YY, Liao W, Wang L. Association between blood calcium, magnesium,and non-alcoholic fatty liver disease in adults: a cohort-based case-controlstudy. Biologic Trace Element Res, doi: 10.1007/s12011-022-03543-6

6.     Feng BY, Chen SH, Wang XM, Hu SQ, ZhangXH, Zhang J, Wu SL, Wang L. Effect of cumulative body mass index exposure andlong-term related change on incident non-alcoholic fatty liver disease. LiverInt, 2023, 43:345-356

7.     Lan YQ, Lu Y, Li JF, Hu SQ, Chen SH, WangYH, Yuan XJ, Liu HM, Wang XM, Wu SL, Wang L. Outcomes of subjects who are lean,overweight or obese with nonalcoholic fatty liver disease: a cohort study inChina. Hepatol commun, 2022, 6:3393-3405 doi:10.1002/hep4.2081

8.      HuSQ, Li XL, Sun YY, Wu SL, Lan YQ, Chen SH, Wang YH, Liao W, Wang XM, Zhang D,Yuan XJ, Gao JL, Wang L.Short-term weight loss decreased the risk of chronic kidney disease in men withincident non-alcoholic fatty liver disease. Obesity,2022,30(7):1495-1506(二区)

9.     胡诗琪，蓝彦琦，吴寿岭，王晓墨，陈朔华，汪国栋，王丽. 肥胖及其变化对中国华北新发NAFLD成年男性患者心血管疾病发病风险的影响[J]. 基础医学与临床, 2022, 42(5):788-794. （核心期刊）

10.   PengHX, Wang SY, Wang MY, Ye Y, Xue E, Chen X, Wang XH, Fan M, Gao WJ, Qin XY, WuYQ, Chen DF, Li J, Hu YH, Wang L, Wu T. Nonalcoholic fatty liver disease andcardiovascular diseases: A Mendelian randomization study. Metabolism, 2022, 133:155220 doi:10.1016/j.metabol.2022.155220

11.  Sun YY, Chen SH, Zhao XY, Wang YH,Lan YQ, Jiang XZ, Gao X, Wu SL, Wang L. Adherence to the dietary approaches tostop hypertension diet and non-alcoholic fatty liver disease. Liverinternational. 2022, 42(4):809-819 doi:10.1111/liv.15156

12.   Zhang D., Wu S., Lan Y., Chen S., Wang Y.,Sun Y., Liao W., Wang L. Blood manganese and nonalcoholic fatty liver disease:a cohort-based case-control study. Chemosphere. 2022, 287: 132316.

13.   Wang X., Wu S., Yuan X., Chen S., Fu Q., Sun Y., Lan Y., Hu S., Wang Y.,Lu Y., Qu S., and Wang L. Metabolic dysfunction-associated fatty liver diseaseand mortality among Chinese adults: a prospective cohort study. J ClinEndocrinol Metab. 2022, 107(2):e745-e755 doi:10.1210/clinem/dgab644.

14.  Wang ZY,Zhao XY, Chen SH, Wang YH, Cao LY, Liao W, Sun YY, WangXM, Zheng Y, Wu SL, Wang L. Associations betweenNonalcoholic fatty liver disease and cancers in a large cohort in China. Clin Gastroenterol Hepatol 2021,19(4): 788-796

15.   Lan Y, Wu S, Wang Y, Chen S, Liao W, ZhangX., Pan L., Jiang X., Zhang Y., Wang L. Association between blood copper andnonalcoholic fatty liver disease according to sex. Clin Nutr. 2021, 40:2045-2052.

16.   Li R., Lin X., Wang J., Wang X., Lu J.,Liu Y., Cao Z., Ren S., Ma L., Jin Y., Zheng S., Hu Z., Wang L., Chen X.Cost-effectiveness of combination antiviral treatment with extended durationfor hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China. AnnTransl Med. 2021, 9: 1365.

17.   Wang X., Chen Y., Xu M., Cheng K., LiaoW., Wang Y., Lu Y., Duan Z., Wang L. Virologic response maintenance andhepatocellular carcinoma in chronic hepatitis B patients treated withentecavir. Expert Rev Gastroenterol Hepatol. 2021, 15: 1337-1344.

18.  LanY., Wang L. Reply-letter to the editor: copper deficiency and nonalcoholicfatty liver disease: the chicken or the egg? Clin Nutr. 2021, 40:5445-5446.

19.   Cheng K., Chen Y., Wang X., Xu M., LiaoW., Duan X., Zhao X., Sun Y., Duan Z., Wang L. Entecavir combined withinterferon-alpha is superior to entecavir monotherapy in reducing hepatic andextrahepatic cancer in patients with chronic hepatitis B. Cancer. 2021,doi: 10.1002/cncr.33949.

20.  Li MM, SunYY, Yang J, Martel Cd, Charvat H, Clifford GM, Vaccarella S, Wang L. Timetrends and other sources of variation in Helicobacter pylori infection inmainland China: a systematic review and meta-analysis. Helicobacter 2020 25:e12729DOI: 10.1111/hel.12729

21.  Lei SY, ChenSH, Zhao XY, Zhang YM, Cheng KL, Zhang XH, Wang ZY, Sun YY, Wu SL, Wang L. HepatitisB virus infection and diabetes mellitus: the Kailuan prospective cohort studyin China. Hepatology international 2020 14：745-753 https://doi.org/10.1007/s12072-020-10086-2

22.  Zheng Y, Xue M, Cai Y, Liao SS, Yang H, Wang ZY, Wang XM,Zhang XG, Qian JM, Wang L. Hospitalizations for Peptic Ulcer Disease in China:current features and outcomes. J Gastroenterol Hepatol 2020, 35: 2122-2130 doi:10.1111/jgh.15119

23.  Zhao XY, Wang N, Sun YY, Zhu GL, Wang YH, Wang ZY, Zhang YM, ChengKL, Wang GD, Wu SL, Wang L. Screen-detectedgallstone disease and risk of liver and pancreatic cancer: The Kailuan CohortStudy. Liver Int 2020, 40:1744-1755. https://doi.org/10.1111/liv.14456

24.  Liu Y, CuXH, Wang XM, Wang ZY, Wang YH, Zhang H, Wang L. Out-of-pocket payments and economic consequences fromtuberculosis care in eastern China: income inequality. Infectious Dis Poverty 2020, 9:14 doi.org/10.1186/s40249-020-0623-8

25.  Lan YQ, Wu SL, Wang YH, Chen SH, Liao W, Zhang XH, Pan L, Jiang XZ,Zhang YM, Wang L. Association between blood copperand nonalcoholic fatty liver disease according to sex. Clin Nutrition 2020 https://doi.org/10.1016/j.clnu.2020.09.026

26.  王振宇, 陈朔华, 赵欣宇, 王艳红, 吴寿岭, 王丽. Cox及其拓展模型在基于队列的依时暴露因素效应估计中的应用.中华流行病学杂志. 2020, 41(6): 957-961